top of page
Asset 1@3x.png

Pioneering the development of novel immunotherapies for patients with blood cancers and B-cell disorders.

News & Events

Two posters, highlighting HaemaLogiX results, will be presented at International Myeloma Society, Athens

Two posters, highlighting HaemaLogiX results, will be presented at International Myeloma Society, Athens

31 August 2023
Read more
We’re pleased to announce that HaemaLogix Chief Scientific Officer Rosanne Dunn has been invited and confirmed to speak at Cell and Gene Therapy World Asia held 14-15 September in Singapore.

HaemaLogiX's CSO, Dr Rosanne Dunn, to speak at Cell and Gene Therapy World Asia, Singapore

14 August 2023
Read more
HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX’s CAR-T cell therapy in patients with kappa-type myeloma

HaemaLogiX to take KMA.CAR-T to Ph1 trial with Peter Mac

25 July 2023
Read more

Our Team

The HaemaLogiX management team has deep expertise in immunotherapy development and the unique antigens that our treatments target. Our Scientific Advisory Board comprises internationally recognised experts in monoclonal antibodies and haematology. 

Asset3@3x.png
Asset 4@3x.png

Our Pipeline

We’re developing a suite of diverse immunotherapies including monoclonal antibodies, CAR-T cells and bispecific antibodies, with a key focus on treating multiple myeloma and early investigation of AL Amyloidosis. 

Our Innovation

Our immunotherapies are designed to target and attack two unique antigens expressed on malignant cells – these antigens are not found on normal cells or tissues - making our treatments unlike others on the market. 

car-t ell.png
bottom of page